WP
VERV

Woodline Partners’s Verve Therapeutics VERV Stock Holding History

Woodline Partners’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,767,719
Closed -$12.6M – 1051
2025
Q1 		$12.6M Buy
+2,767,719
New +$18.5M 0.08% 319
2024
Q2 		– Sell
-521,112
Closed -$6.92M – 678
2024
Q1 		$6.92M Buy
521,112
+23
+0% +$305 0.06% 325
2023
Q4 		$7.26M Sell
521,089
-171
-0% -$2.12K 0.08% 266
2023
Q3 		$6.91M Buy
521,260
+126,839
+32% +$2.04M 0.08% 267
2023
Q2 		$7.4M Buy
394,421
+7,955
+2% +$132K 0.09% 244
2023
Q1 		$5.57M Buy
386,466
+10,189
+3% +$200K 0.08% 278
2022
Q4 		$7.28M Buy
376,277
+1,282
+0.3% +$34K 0.1% 262
2022
Q3 		$12.9M Buy
374,995
+224,995
+150% +$7.18M 0.18% 165
2022
Q2 		$2.29M Hold
150,000
– – 0.04% 406
2022
Q1 		$3.42M Sell
150,000
-26,027
-15% -$744K 0.06% 295
2021
Q4 		$6.49M Sell
176,027
-26,473
-13% -$1.11M 0.09% 253
2021
Q3 		$9.52M Sell
202,500
-4,421
-2% -$260K 0.16% 170
2021
Q2 		$12.5M Buy
+206,921
New +$8.59M 0.23% 113

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners's VERV Position: Q2 2025 in Review

Woodline Partners sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 2,767,719 shares — an estimated $12.6M sold.

Woodline Partners first reported a position in VERV in Q2 2021 and held it in 13 quarters. The position peaked at $12.9M in Q3 2022. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Woodline Partners reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 2,767,719 Verve Therapeutics shares in Q2 2025, an estimated $12.6M.
  • Woodline Partners first reported a position in Verve Therapeutics in Q2 2021 and held it in 13 quarters.
  • Woodline Partners's Verve Therapeutics position peaked at $12.9M in Q3 2022.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.